Why the Generics and Biosimilar Market is Redefining Private Equity Success
For years, the generics and biosimilar industries have been defined by stability and volume—a reliable but low-margin foundation. Today, Private Equity (PE) is transforming this narrative, moving beyond traditional financial engineering to become a primary force for operational excellence and unprecedented value creation.
This new 15-page analysis from Parsity Group provides senior PE investors, Generics CEOs, and Biosimilar leaders with the strategic blueprint required to identify, acquire, and transform assets in this critical sector.
Download the Report to Discover:
The €1.9B to €4.1B Blueprint: A detailed breakdown of the Zentiva case study, revealing how a corporate ‘carve-out’ was successfully transformed under PE ownership, more than doubling its revenue and EBITDA.
The Investment Thesis Defined: Quantitative proof of why a market accounting for 90% of all US prescriptions, yet only 13.1% of spending, offers a stable, recession-resistant revenue base for aggressive strategies.
The Talent Factor: The critical, often unstated, competitive advantage of PE—the strategic deployment of visionary C-level executives and hands-on operating partners who are directly responsible for execution.
The Value Creation Matrix: A data-driven view showing that Revenue Growth accounts for 54% of PE value created, driven primarily by effective ‘buy-and-build’ strategies.
Navigating Complexity: Analysis of the steep technical barriers and talent scarcity in the biosimilar segment, and how well-capitalised players mitigate these risks.
Who Should Read This Report?
This white paper is essential reading for:
Senior Investment Partners and Principals at Private Equity firms.
CEOs, COOs, and Divisional Heads within Generics and Biosimilar manufacturing.
Specialist Operating Partners focused on value creation in the life sciences.
Stop leaving value on the table. The playbook has been written. Download the full strategic analysis now.